163 related articles for article (PubMed ID: 15605615)
21. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
[TBL] [Abstract][Full Text] [Related]
22. Peak pressures: crossover study of timolol and latanoprost.
Sihota R; Saxena R; Agarwal HC; Pandey RM; Gulati V
Eur J Ophthalmol; 2003 Jul; 13(6):546-52. PubMed ID: 12948313
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure.
Shin DH; Feldman RM; Sheu WP;
Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375
[TBL] [Abstract][Full Text] [Related]
24. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination.
Inoue K; Okayama R; Higa R; Sawada H; Wakakura M; Tomita G
J Ocul Pharmacol Ther; 2011 Dec; 27(6):581-7. PubMed ID: 22011049
[TBL] [Abstract][Full Text] [Related]
25. The Efficacy of a Latanoprost/Timolol Fixed Combination Versus Latanoprost and Timolol Gel-forming Solution Unfixed Combination on Daytime Intraocular Pressure.
Özyol E; Özyol P
J Glaucoma; 2016 Feb; 25(2):135-9. PubMed ID: 25264990
[TBL] [Abstract][Full Text] [Related]
26. Switching from latanoprost to fixed-combination latanoprost-timolol: a 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension.
Olander K; Zimmerman TJ; Downes N; Schoenfelder J;
Clin Ther; 2004 Oct; 26(10):1619-29. PubMed ID: 15598478
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of latanoprost versus pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension.
Kałuzny J; Sobecki R; Czechowicz-Janicka K; Kecik D; Kałuzny BJ; Stewart JA; Stewart WC
Acta Ophthalmol; 2008 Dec; 86(8):860-5. PubMed ID: 18721251
[TBL] [Abstract][Full Text] [Related]
28. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
29. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components.
Diestelhorst M; Larsson LI;
Ophthalmology; 2006 Jan; 113(1):70-6. PubMed ID: 16263174
[TBL] [Abstract][Full Text] [Related]
30. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
[TBL] [Abstract][Full Text] [Related]
31. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients.
Hedman K; Larsson LI
Surv Ophthalmol; 2002 Aug; 47 Suppl 1():S77-89. PubMed ID: 12204703
[TBL] [Abstract][Full Text] [Related]
32. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group.
Camras CB
Ophthalmology; 1996 Jan; 103(1):138-47. PubMed ID: 8628544
[TBL] [Abstract][Full Text] [Related]
33. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.
Alm A; Stjernschantz J
Ophthalmology; 1995 Dec; 102(12):1743-52. PubMed ID: 9098273
[TBL] [Abstract][Full Text] [Related]
34. A comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trial.
Facio AC; Reis AS; Vidal KS; de Moraes CG; Suzuki R; Hatanaka M; Susanna R
J Ocul Pharmacol Ther; 2009 Oct; 25(5):447-51. PubMed ID: 19860553
[TBL] [Abstract][Full Text] [Related]
35. Short-term tolerability of once-daily timolol hemihydrate 0.5%, timolol maleate in sorbate 0.5%, and generic timolol maleate gel-forming solution 0.5% in glaucoma and/or ocular hypertension: a prospective, randomized, double-masked, active-controlled, three-period crossover pilot study.
Sonty S; Mundorf TK; Stewart JA; Stewart WC
Clin Ther; 2009 Oct; 31(10):2063-71. PubMed ID: 19922877
[TBL] [Abstract][Full Text] [Related]
36. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure.
Jampel HD; Bacharach J; Sheu WP; Wohl LG; Solish AM; Christie W;
Am J Ophthalmol; 2002 Dec; 134(6):863-71. PubMed ID: 12470755
[TBL] [Abstract][Full Text] [Related]
37. Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension.
Netland PA; Robertson SM; Sullivan EK; Silver L; Bergamini MV; Krueger S; Weiner AL; Davis AA;
Adv Ther; 2003; 20(3):149-63. PubMed ID: 12956257
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.
Fechtner RD; Airaksinen PJ; Getson AJ; Lines CR; Adamsons IA;
Acta Ophthalmol Scand; 2004 Feb; 82(1):42-8. PubMed ID: 14982045
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours.
Liu JHK; Slight JR; Vittitow JL; Scassellati Sforzolini B; Weinreb RN
Am J Ophthalmol; 2016 Sep; 169():249-257. PubMed ID: 27457257
[TBL] [Abstract][Full Text] [Related]
40. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
